Actively Recruiting
Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer
Led by Tyler J Curiel · Updated on 2026-01-28
33
Participants Needed
2
Research Sites
172 weeks
Total Duration
On this page
Sponsors
T
Tyler J Curiel
Lead Sponsor
D
Dartmouth-Hitchcock Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.
CONDITIONS
Official Title
Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Able and willing to provide informed consent
- Histologically confirmed high-grade serous ovarian carcinoma
- Platinum-resistant or refractory ovarian cancer with progression within 6 months of last platinum treatment
- Planned to receive allowable standard of care chemotherapy regimens for ovarian cancer
- Life expectancy of 2 months or more
- Adequate bone marrow function: ANC 61.5 x 10^9/L, platelet count 100 x 10^9/L, hemoglobin 8 g/dL without recent transfusion
- Adequate liver function: total bilirubin 1.5 x institutional upper limit of normal (IULN), AST 2.5 x IULN, ALT 2.5 x IULN
- Adequate kidney function: creatinine 1.5 x IULN or creatinine clearance 40 mL/min
- Adequate coagulation: INR or prothrombin time 1.5 x IULN and aPTT 1.5 x IULN unless on anticoagulants
- Female patients of childbearing potential must use highly effective contraception during the study and for 3 months after chemotherapy
- Female patients of childbearing potential must have a negative serum pregnancy test within 72 hours before first study dose
- Non-childbearing potential defined by age 5 years with no menses for >1 year, amenorrheic >2 years with postmenopausal hormone levels, post-hysterectomy/oophorectomy/tubal ligation status, or genetic defect preventing pregnancy
- No contraindications to telmisartan including no ACE inhibitor use within 6 weeks prior to telmisartan
- Systolic blood pressure 110 mm Hg during screening and study
You will not qualify if you...
- Unable to provide informed consent
- Known significant liver disease including active viral, alcoholic, or other hepatitis, or cirrhosis
- Chronic hepatitis B with detectable viral load or untreated hepatitis C infection
- Hypertensive urgency or emergency
- Incarcerated or homeless
- Pregnant or lactating
- Under 18 years of age
- Receiving lithium therapy
- Received rituximab or amifostine within 30 days before starting telmisartan
- Active serious infection requiring treatment
- Active cardiovascular disease including stroke, myocardial infarction within 6 months, unstable angina, congestive heart failure class II or higher, or uncontrolled cardiac arrhythmia requiring medication
- Any condition or therapy that could interfere with trial participation or results
- Taking ramapril
- Using bevacizumab as part of standard chemotherapy
- HIV infection with detectable viral load
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Dartmouth Hitchcock
Lebanon, New Hampshire, United States, 03756
Actively Recruiting
2
Dartmouth-Hitchcock Manchester
Manchester, New Hampshire, United States, 03104
Actively Recruiting
Research Team
K
Kayla Fay
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here